2022-13290. Foreign-Trade Zone (FTZ) 99-Wilmington, Delaware; Authorization of Production Activity; AstraZeneca Pharmaceuticals, LP (Pharmaceutical Products), Newark, Delaware

On February 16, 2022, AstraZeneca Pharmaceuticals, LP submitted a notification of proposed production activity to the FTZ Board for its facility within Subzone 99D, in Newark, Delaware.

The notification was processed in accordance with the regulations of the FTZ Board (15 CFR part 400), including notice in the Federal Register inviting public comment (87 FR 10771, February 25, 2022). On June 16, 2022, the applicant was notified of the FTZ Board's decision that no further review of the activity is warranted at this time. The production activity described in the notification was authorized, subject to the FTZ Act and the FTZ Board's regulations, including Section 400.14.

Dated: June 16, 2022.

Andrew McGilvray,

Executive Secretary.